State Board of Administration of Florida Retirement System Buys 140 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

State Board of Administration of Florida Retirement System raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report) by 0.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 92,059 shares of the biotechnology company’s stock after purchasing an additional 140 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Sarepta Therapeutics were worth $11,159,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Spire Wealth Management boosted its holdings in shares of Sarepta Therapeutics by 3,666.7% during the 2nd quarter. Spire Wealth Management now owns 226 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 220 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Sarepta Therapeutics by 308.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 245 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. KB Financial Partners LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at $36,000. AlphaCentric Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at $45,000. Finally, Industrial Alliance Investment Management Inc. acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 91.82% of the company’s stock.

Sarepta Therapeutics Stock Up 0.4 %

SRPT opened at $127.32 on Tuesday. The stock has a market cap of $11.91 billion, a PE ratio of -16.26 and a beta of 0.93. The company has a quick ratio of 4.90, a current ratio of 5.44 and a debt-to-equity ratio of 1.62. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $159.89. The business’s fifty day simple moving average is $106.99 and its 200 day simple moving average is $106.53.

Wall Street Analysts Forecast Growth

Several research analysts have commented on SRPT shares. Oppenheimer downgraded Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 31st. Citigroup started coverage on Sarepta Therapeutics in a report on Wednesday, December 13th. They set a “buy” rating and a $113.00 target price on the stock. Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a report on Tuesday, December 12th. They set a “buy” rating and a $109.00 target price on the stock. BMO Capital Markets started coverage on Sarepta Therapeutics in a report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 target price on the stock. Finally, Barclays lowered their price objective on Sarepta Therapeutics from $193.00 to $141.00 and set an “overweight” rating for the company in a research report on Thursday, November 2nd. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $153.10.

Get Our Latest Stock Report on Sarepta Therapeutics

Sarepta Therapeutics Profile

(Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene.

See Also

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.